UB Paderborn / Katalog / Suche / in CDI

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

Journal of clinical oncology, 2005-06, Vol.23 (16), p.3676-3685

2005

Volltextzugriff (PDF)

The Use of Alternate, Non–Cross-Resistant Adjuvant Chemotherapy on the Basis of Pathologic Response to a Neoadjuvant Doxorubicin-Based Regimen in Women With Operable Breast Cancer: Long-Term Results From a Prospective Randomized Trial

Journal of clinical oncology, 2004-06, Vol.22 (12), p.2294-2302

2004

Volltextzugriff (PDF)

Capecitabine-based combination therapy for breast cancer: implications for nurses

Oncology nursing forum, 2009-01, Vol.36 (1), p.105-113

Frye, Debra K

2009

Volltextzugriff (PDF)

Advances in breast cancer treatment: the emerging role of ixabepilone

Expert review of anticancer therapy, 2010-01, Vol.10 (1), p.23-32

Frye, Debra K

2010

Volltextzugriff (PDF)

Evaluation of Paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: Preliminary data of a prospective randomized trial

Clinical cancer research, 2002-05, Vol.8 (5), p.1073-1079

2002

Volltextzugriff (PDF)

Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy

The cancer journal (Sudbury, Mass.), 2008-01, Vol.14 (1), p.62-68

2008

Volltextzugriff (PDF)

Recommendations for Enhancing Clinical Trials Education: a Review of the Literature

Journal of cancer education, 2011-03, Vol.26 (1), p.64-71

2011

Volltextzugriff (PDF)

Phase I Study of Prolonged-Infusion Gemcitabine Combined with Cyclophosphamide in Patients with Metastatic Carcinoma of the Breast: Tolerability of an Optimal Dose Schedule

Oncology, 2009-01, Vol.77 (1), p.63-70

2009

Volltextzugriff (PDF)

New Options for Metastatic Breast Cancer

Clinical journal of oncology nursing, 2009-02, Vol.13, p.11-18

2009

Volltextzugriff (PDF)

Current Clinical Issues in Systemic Therapy for Metastatic Breast Cancer

Clinical journal of oncology nursing, 2009-02, Vol.13, p.4-10

2009

Volltextzugriff (PDF)

Phase I study of eniluracil and oral 5‐fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma

Cancer, 2002-05, Vol.94 (9), p.2321-2326

2002

Volltextzugriff (PDF)

Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer

JNCI : Journal of the National Cancer Institute, 1991-12, Vol.83 (24), p.1797-1805

1991

Volltextzugriff (PDF)

Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer

Journal of clinical oncology, 1997-10, Vol.15 (10), p.3171-3177

1997

Volltextzugriff (PDF)

Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up : the M.D. Anderson experience

Cancer chemotherapy and pharmacology, 1999, Vol.43 (6), p.471-478

1999

Volltextzugriff (PDF)

The prognostic significance of sialyl‐tn Antigen in women treated with breast carcinoma treated with adjuvant chemotherapy

Cancer, 1997-12, Vol.80 (12), p.2240-2249

1997

Volltextzugriff (PDF)

Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy

The cancer journal (Sudbury, Mass.), 2001-09, Vol.7 (5), p.413

2001

Volltextzugriff (PDF)

Evaluation of Paclitaxel in Adjuvant Chemotherapy for Patients with Operable Breast Cancer

Clinical cancer research, 2002-05, Vol.8 (5), p.1073

2002

Volltextzugriff (PDF)

Taxane Chemotherapy—Advances in Treatment for Breast Cancer

Oncology & Hematology Review (US), 2006 (1), p.40

Frye, Debra K

2006

Volltextzugriff (PDF)

Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer

Breast cancer research and treatment, 1991-08, Vol.18 (3), p.165-170

1991

Volltextzugriff (PDF)

Combined Modality Treatment of Stage III and Inflammatory Breast Cancer

Surgical oncology clinics of North America, 1995-10, Vol.4 (4), p.715-734

1995

Volltextzugriff (PDF)

Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome

Archives of internal medicine (1960), 1996-04, Vol.156 (8), p.882-888

Ibrahim, N. K.

1996

Volltextzugriff (PDF)

Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome

Archives of internal medicine (1960), 1996-04, Vol.156 (8), p.882

1996

Volltextzugriff (PDF)

TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma

Cancer immunology research, 2019-10, Vol.7 (10), p.1672-1686

2019

Volltextzugriff (PDF)

Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks

Journal of clinical oncology, 2005-09, Vol.23 (25), p.5983-5992

2005

Volltextzugriff (PDF)

UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor

Journal of medicinal chemistry, 2014-08, Vol.57 (16), p.7031-7041

2014

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

The Use of Alternate, Non–Cross-Resistant Adjuvant Chemotherapy on the Basis of Pathologic Response to a Neoadjuvant Doxorubicin-Based Regimen in Women With Operable Breast Cancer: Long-Term Results From a Prospective Randomized Trial

Capecitabine-based combination therapy for breast cancer: implications for nurses

Advances in breast cancer treatment: the emerging role of ixabepilone

Evaluation of Paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: Preliminary data of a prospective randomized trial

Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy

Recommendations for Enhancing Clinical Trials Education: a Review of the Literature

Phase I Study of Prolonged-Infusion Gemcitabine Combined with Cyclophosphamide in Patients with Metastatic Carcinoma of the Breast: Tolerability of an Optimal Dose Schedule

New Options for Metastatic Breast Cancer

Current Clinical Issues in Systemic Therapy for Metastatic Breast Cancer

Phase I study of eniluracil and oral 5‐fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma

Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer

Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer

Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up : the M.D. Anderson experience

The prognostic significance of sialyl‐tn Antigen in women treated with breast carcinoma treated with adjuvant chemotherapy

Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy

Evaluation of Paclitaxel in Adjuvant Chemotherapy for Patients with Operable Breast Cancer

Taxane Chemotherapy—Advances in Treatment for Breast Cancer

Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer

Combined Modality Treatment of Stage III and Inflammatory Breast Cancer

Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome

Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome

TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma

Weekly Paclitaxel Improves Pathologic Complete Remission in Operable Breast Cancer When Compared With Paclitaxel Once Every 3 Weeks

UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor

Suchergebnisse filtern